Shares of Allena Pharmaceuticals Inc (NASDAQ:ALNA) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus target price of $26.00 for the company and are expecting that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also given Allena Pharmaceuticals an industry rank of 179 out of 265 based on the ratings given to its competitors.

ALNA has been the subject of a number of analyst reports. Credit Suisse Group initiated coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $22.00 price target for the company. Wedbush initiated coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $30.00 price target for the company. Cowen initiated coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Finally, Jefferies Group initiated coverage on Allena Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $22.00 price target for the company.

In other Allena Pharmaceuticals news, Director James N. Topper bought 500,000 shares of Allena Pharmaceuticals stock in a transaction dated Monday, November 6th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $7,000,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of Allena Pharmaceuticals stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $14.00 per share, with a total value of $504,000.00. The disclosure for this purchase can be found here.

Shares of Allena Pharmaceuticals (ALNA) traded down $0.07 during trading on Wednesday, reaching $9.65. The company had a trading volume of 70,744 shares, compared to its average volume of 80,347. Allena Pharmaceuticals has a 1-year low of $8.66 and a 1-year high of $15.40. The firm has a market cap of $198.03 and a price-to-earnings ratio of -9.37. The company has a debt-to-equity ratio of -0.09, a quick ratio of 4.83 and a current ratio of 4.83.

Allena Pharmaceuticals (NASDAQ:ALNA) last announced its earnings results on Thursday, December 14th. The company reported ($3.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($3.11). analysts anticipate that Allena Pharmaceuticals will post -0.89 EPS for the current fiscal year.

WARNING: “Brokerages Anticipate Allena Pharmaceuticals Inc (ALNA) to Post ($0.33) Earnings Per Share” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.dailypolitical.com/2018/01/20/brokerages-anticipate-allena-pharmaceuticals-inc-alna-to-post-0-33-earnings-per-share.html.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.